Phase 3 Motor Neurone Disease Trial, Recruiting NCT06719947 Sponsor: Universidade Federal do Rio Grande do Norte Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Phase 3 Motor Neurone Disease Trial, Recruiting

NCT06719947
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People of any sex who have been diagnosed with ALS (Lou Gehrig's disease) using a standard set of medical guidelines called the revised El Escorial criteria
  • People between 18 and 80 years old
  • People whose lungs are working at more than 50% of the expected capacity for someone their age and size
  • People whose breathing muscle strength (measured by a specific sniff test through the nose) is above a certain level (confirm with trial site if unsure what this means for you)
  • People who have a phone number where the care team can reach them and who have signed the study consent form

Who may not be able to join:

  • People who are unable to understand or follow the study procedures
  • People who do not wish to take part, or who decide at any point they want to leave the study
  • People who have heart, lung, or muscle/bone conditions in addition to their ALS diagnosis
  • People who are already using a breathing machine that works through a tube inserted into the airway (invasive mechanical ventilation)
  • People who have had a surgical opening made in their throat to help with breathing (tracheostomy)
  • People who have a pacemaker (a small device implanted in the chest to help the heart beat regularly)
  • People who have any metal implants in the brain or other electronic implants in the body
  • People who have a cochlear implant (a hearing device surgically placed in the ear)
  • People who have epilepsy, a personal history of seizures, or a family history of epilepsy
  • People who have had a stroke or a tumor at any point in their life
  • People who are prone to sudden changes in blood pressure or heart rate, active infections, or inflammatory conditions
  • Women who are pregnant at the time of joining the study
  • People who are unlikely to be able to complete all parts of the study program

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +55(84)99426-7896

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Universidade Federal do Rio Grande do Norte
Registry
ClinicalTrials.gov
Start date
28 November 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇧🇷 Brazil 🇨🇱 Chile

Primary endpoints

Cortical excitability assessed via TMS; Cortical tissue oxygenation; Electromyographic activity of specific respiratory muscles

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov